Travere Therapeutics (TVTX) Misses Q2 EPS by 6c, beats revenue

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($1.13), $0.06 worse than the analyst estimate of ($1.07). Revenue for the quarter came in at $57 million versus the consensus estimate of $53.71 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Hyperscale Data launches $300M at-the-market stock offering